The present disclosure relates to anti-cancer compositions, and associated methods, including an anti-cancer composition comprising: a cellular energy inhibitor having the structure according to formula I (I) wherein X is selected from the group consisting of: a nitro, an imidazole, a halide, sulfonate, a carboxylate, an alkoxide, and amine oxide； and R is selected from the group consisting of: OR&rsquo；, N(R&rdquo；)2, C(O)R&rdquo；&rsquo；, C 1 -C6 alkyl, C6-C 12 aryl, C1 -C6 heteroalkyl, a C6-C12 heteroaryl, H, and an alkali metal； where R1 represents H, alkali metal, C 1-C6 alkyl, C6-C12 aryl or C(O)R&rsquo；&rdquo；, R&rdquo； represents H, C 1 -C6 alkyl, or C6-C 12 aryl, and R&rsquo；&rdquo； represents H, C1 -C20 alkyl or C6-C 12 aryl. The anti-cancer composition can additionally comprise at least one sugar, which stabilizes the cellular energy inhibitor by substantially preventing the inhibitor from hydrolyzing. Also, the anti-cancer composition can comprise a glycolysis inhibitor including 2-deoxyglucos. Further, the anti-cancer composition can comprise a biological buffer, including citrate that is present in an amount sufficient to at least partially deacidify the cellular energy inhibitor and neutralize metabolic by-products of the cellular energy inhibitor.
